S&P 500: 681.75 +0.1% NASDAQ 100: 601.92 +0.2% Dow Jones: 495.28 +0.1%

George Soros’s RNA Holdings & Trades

First Buy
Q4 2025
Duration Held
1 Quarters
Largest Add
Q4 2025
+840,976 Shares
Current Position
840,976 Shares
$60.66 M Value

George Soros's RNA Position Overview

George Soros (via Soros Fund Management LLC) currently holds 840,976 shares of Avidity Biosciences, Inc. (RNA) worth $60.66 M, representing 0.70% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.

Based on recent 13F filings, George Soros has initiated a new position in RNA, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

George Soros's Avidity Biosciences (RNA) Holding Value Over Time

Track share changes against reported price movement

Quarterly Avidity Biosciences (RNA) Trades by George Soros

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +840,976 New Buy 840,976 $72.13

George Soros's Avidity Biosciences Investment FAQs

George Soros first purchased Avidity Biosciences, Inc. (RNA) in Q4 2025, acquiring 840,976 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

George Soros has held Avidity Biosciences, Inc. (RNA) for 1 quarters since Q4 2025.

George Soros's largest addition to Avidity Biosciences, Inc. (RNA) was in Q4 2025, adding 840,976 shares worth $60.66 M.

According to the latest 13F filing for Q4 2025, George Soros's firm, Soros Fund Management LLC, owns 840,976 shares of Avidity Biosciences, Inc. (RNA), valued at approximately $60.66 M.

As of the Q4 2025 filing, Avidity Biosciences, Inc. (RNA) represents approximately 0.70% of George Soros's publicly disclosed stock portfolio, making it one of their key holdings.

George Soros's peak holding in Avidity Biosciences, Inc. (RNA) was 840,976 shares, as reported at the end of Q4 2025.